Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: A first critical step for rational design of innovative regimens

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5303-5308

  Hope, William W ^a,b   Goodwin, Joanne ^a,b   Felton, Timothy W ^a   Ellis, Michael ^c   Stevens, David A ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ADOLESCENT; ADULT; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MONTE CARLO METHOD; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 84866338402     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00933-12     Document Type: Article

References (33)

1. Adler-Moore JP, Olson JA, Proffitt RT. 2004. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J. Antimicrob. Chemother. 54:1096-1102. (Pubitemid 40136748)
2. Andes D, Safdar N, Marchillo K, Conklin R. 2006. Pharmacokinetic- pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother. 50:674-684. (Pubitemid 43190982)
3. Andes D, Stamsted T, Conklin R. 2001. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob. Agents Chemother. 45:922-926. (Pubitemid 32182046)
4. Bekersky I, et al. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833. (Pubitemid 34157670)
5. Bekersky I, et al. 2002. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46:834-840. (Pubitemid 34157671)
6. Cordonnier C, et al. 2008. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int. J. Antimicrob. Agents 31:135-141.
7. Cornely OA, et al. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44:1289-1297.
8. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
9. Denning DW, Hope WW. 2010. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 18:195-204.
10. El-Cheikh J, et al. 2007. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 39:301-306. (Pubitemid 46322637)
11. Ellis M. 2008. New dosing strategies for liposomal amphotericin B in high-risk patients. Clin. Microbiol. Infect. 14(Suppl 4):55-64. (Pubitemid 351593917)
12. Ellis M, et al. 2009. A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever. J. Med. Microbiol. 58:1474-1485.
13. Garcia A, Adler-Moore JP, Proffitt RT. 2000. Single-dose AmBisome (liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis. Antimicrob. Agents Chemother. 44:2327-2332. (Pubitemid 30650875)
14. Groll AH, et al. 2006. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob. Agents Chemother. 50:3418-3423. (Pubitemid 44527518)
15. Gubbins PO, Amsden JR, McConnell SA, Anaissie EJ. 2009. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients. Antimicrob. Agents Chemother. 53:3664-3674.
16. Hamill RJ, et al. 2010. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin. Infect. Dis. 51:225-232.
17. Howard SJ, et al. 2011. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob. Agents Chemother. 55:4880-4887.
18. Kuse ER, et al. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527.
19. Lanternier F, et al. 2012. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin. Infect. Dis. 54(Suppl 1):S35-S43.
20. Leary R, Jelliffe R, Schumitzky A, van Guilder M. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p 389-394. In Proceedings of the Fourteenth IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Washington, DC.
21. Lee JW, et al. 1994. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. 38:713-718. (Pubitemid 24114006)
22. Lestner JM, et al. 2010. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 54:3432-3441.
23. Macdonald I, Staatz CE, Jelliffe RW, Thomson AH. 2008. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther. Drug Monit. 30:67-74. (Pubitemid 351161101)
24. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
25. Tam VH, Preston SL, Drusano GL. 2003. Optimal sampling schedule design for populations of patients. Antimicrob. Agents Chemother. 47: 2888-2891. (Pubitemid 37040264)
26. Vogelsinger H, et al. 2006. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J. Antimicrob. Chemother. 57:1153-1160. (Pubitemid 44644419)
27. Walsh TJ, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46: 327-360. (Pubitemid 351265310)
28. Walsh TJ, et al. 1999. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340: 764-771. (Pubitemid 29114295)
29. Walsh TJ, et al. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45:3487-3496. (Pubitemid 33107867)
30. Walsh TJ, et al. 1998. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42:2391-2398. (Pubitemid 28420384)
31. Wasan KM, Lopez-Berestein G. 1996. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin. Infect. Dis. 23:1126-1138. (Pubitemid 26367503)
32. Weiler S, et al. 2009. Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations. Antimicrob. Agents Chemother. 53:4934-4937.
33. Wurthwein G, et al. 2012. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob. Agents Chemother. 56:536-543.